|
Main characteristics of patients receiving ovarian stimulation by highly purified urinary human follicle stimulating hormone (HP-uFSH) or recombinant human follicle stimulating hormone (rFSH) (* values are expressed as mean ± SD; ns = not significant) |
||||
| Overall |
HP-uFSH |
rFSH |
p |
|
|
|
||||
| N. of patients |
260 |
130 |
130 |
|
| Age (years) * |
32.7 ± 4.3 |
33.0 ± 3.6 |
32.3 ± 4.0 |
ns |
| BMI (kg/m2) * |
21.5 ± 3.4 |
21.2 ± 3.0 |
21.3 ± 3.1 |
ns |
| Duration of infertility (years) * |
2.6 ± 1.5 |
2.7 ± 1.4 |
2.5 ± 1.4 |
ns |
| Type of infertility (%): |
||||
| Primary |
196 |
97 (74.6) |
99 (76.1) |
ns |
| Secondary |
64 |
33 (25.4) |
31 (23.9) |
ns |
| Indication to treatment (%): |
||||
| unexplained infertility |
184 |
91 (70.0) |
93 (71.5) |
ns |
| CC-resistant PCOS |
76 |
39 (30.0) |
37 (28.5) |
ns |
| LH/FSH * |
1.4 ± 0.6 |
1.3 ± 0.9 |
1.4 ± 0.9 |
ns |
| Testosterone (ng/mL) * |
0.6 ± 0.8 |
0.6 ± 0.5 |
0.7 ± 0.1 |
ns |
| Prolactin (ng/mL) * |
17.9 ± 4.1 |
17.7 ± 4.0 |
18.3 ± 3.8 |
ns |
Revelli et al. Reproductive Biology and Endocrinology 2006 4:38 doi:10.1186/1477-7827-4-38 |
||||